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BACKGROUND: Effective and enforceable national regulations describing the manufacture and 
(re)packaging, export and import, distribution and storage, supply and sale, information and pharmaco-
vigilance of medicines are required to consistently ensure optimal patient benefit. Expansion of 
pharmaceutical industries in many countries with advancement in transport technologies facilitated not 
only trade of genuine pharmaceutical products but also the circulation of poor quality medicines across 
the globe. In Ethiopia, even though “The Pharmacists and Druggists Proclamation No 43/1942” was 
used to regulate both the professions and the facilities where they were practiced, comprehensive 
regulation of the pharmaceutical market was introduced in 1964 by a regulation called “Pharmacy 
Regulation No. 288/ 1964”.  This legislation formed the legal basis for official establishment of drug 
regulation in the history of Ethiopia, enabling the regulation of the practice of pharmacists, druggists 
and pharmacy technicians; manufacturing, distribution, and sale of medicines. In June 1999, a new 
regulation called the “Drug Administration and Control Proclamation No. 176/1999” repealed most 
parts of the regulation 288/1964. The law established an independent Drug Administration and Control 
Authority (DACA) with further mandate of setting standards of competence for licensing 
institutions/facilities. DACA was re-structured as Food, Medicine and Health Care Administration and 
Control Authority (EFMHACA) of Ethiopia by the “Proclamation No. 661/2009” in 2010 bearing 
additional responsibilities like regulation of food, health care personnel and settings. The mere existence 
of this legal framework does not guarantee complete absence of illegal, substandard and falsified 
products as well as illegal establishments in the pharmaceutical chain. Therefore, the objective of the 
research is to assess the pharmaceutical regulatory system in Ethiopia and to reveal possible reasons for 
deficiencies in the pharmaceutical chain.  
METHODS: An archival review, an in-depth interview of key informants and an institutions-based 
cross-sectional survey study were conducted during March to April 2013. The comprehensiveness of the 
pharmaceutical law to protect public health relative to three selected African countries (South Africa, 
Tanzania and Uganda) and European Union, and implementation was assessed.   
RESULTS: The study revealed that Ethiopia does have a written national drug policy upon which the 
Medicines Regulatory Proclamation 661/2009 is based. According to this proclamation, the Ethiopian 
The Food, Medicines and Healthcare Administration and Control Authority is mandated to execute the 
regulatory activities as per the council of ministers regulation 189/2010. The legal framework for  
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pharmaceutical regulation of Ethiopia was founded to fulfill all the medicines regulatory functions 
potentially enabling to combat illegal, substandard and falsified medicines and illegal establishments. 
Moreover, all the key informants witnessed that the government is commited and proclamation 661/2009 
is comprehensive, but they stressed the compelling need of regulatory tools for effective implementation. 
From the institution-based cross-sectional study, it was revealed that there exist illegal sources 
formedicine in the pharmaceutical market. The main reasons for their existence were regulatory factors 
including weak regulatory enforcement (64.5%), lack of informal market control (60.8%), weak port 
control (50.0%), and poor cooperation between executive bodies (39.6%); and resource constraint 
(27.8%), which is an institutional factor. 
CONCLUSIONS: From legislative point of view, the medicines regulatory framework in Ethiopia fulfils 
all regulatory functions required  for effective medicines regulation. However, the existence of the 
legislation by its own is not a guarantee to prevent the existence of unauthorized/illegal medicine sources 
since this requires effective implementation of the legislation, which is in fact affected by the 
governments political commitment, resource and intergovernmental cooperation. 
KEYWORDS: Drug policy, Pharmaceutical legislation, Medicines regulation, 






The fundamental purpose of medicine regulation 
is to protect public health and to ensure that 
medicines on national markets and in international 
commerce are safe, effective and of good quality, 
and used in accordance with good practices. 
Medicines are important aspects of public health 
and must be available and accessible to the public.  
To improve access to medicines, good governance 
is crucial and contributes to health systems 
strengthening. Good governance in the 
pharmaceutical sector refers to the formulation 
and implementation of appropriate policies and 
procedures that ensure the effective, efficient and 
ethical management of medicine regulation, in a 
manner that is transparent, accountable and 
follows the rule of law (1-4).  
Since the mid-1930s, many new 
pharmaceutical products have flourished and trade 
in the pharmaceutical industry has taken on 
international dimensions. However, the circulation 
of toxic, substandard and counterfeit drugs on the 
national and international market has increased. 
This is mainly due to ineffective regulation of 
production and trade in pharmaceutical products in 
both exporting and importing countries. The use of 
these poor quality medicines may also threaten the 
health and lives of patients (5). WHO estimates 
that from one million deaths that occur from 
malaria annually, 200,000 would be avoidable if 
the medicines available were effective, of good 
quality and used correctly. A study conducted in 
Southeast Asia in 2001 revealed that 38% of 104 
anti-malarial drugs on sale in pharmacies did not 
contain any active ingredient and resulted in a 
number of preventable deaths (6). Moreover, in-
efficiencies in medicines regulatory system can 
delay entry of needed medicines in a market; 
hence, a barrier to access for users and to the 
profits and growth of the pharmaceutical business 
(7).  
According to WHO, about 20% of countries 
have well-developed and operational medicines 
regulation. Of the rest, approximately half have 
regulation of varying capacity and level of 
development, and 30% have either no or very 
limited medicines regulation; revealing that many 
low-income countries cannot ensure safety, 
efficacy and quality of medicines circulating on 
their markets. The problems of ineffective 
regulation have global implications (8) and 
minimum requirements for effective medicines 
regulation should exist in any country to counter 
poor quality medicines (9).  
The situation is severe in sub-Saharan 
African countries where there are limited 
resources and pharmaceutical manufacturing 
capacity with a high disease burden. Thus, 
parallel, unregulated medicines markets are posing 
serious risks for individual and public health (10). 
As far as Ethiopia is concerned, there is no 
comprehensive evaluation of the basic medicines 
regulatory framework and associated unregulated 
medicines and their sources.  




Ethiopia is one of the sub-Saharan African 
countries where the pharmaceutical sector is being 
guided by a national medicine policy (11). “The 
Pharmacists and Druggists Proclamation No 
43/1942” was the basis for pharmaceutical 
regulation where both pharmacists and druggists 
together with the facilities where they practiced 
were regulated. Comprehensive regulation of the 
pharmaceutical sector was started in the early 
stages by a regulation called “Pharmacy 
Regulation No. 288/ 1964”, which formed the 
legal basis for official establishment of drug 
regulation in the history of Ethiopia. The 
Pharmacy and Laboratory Department under the 
then Ministry of Health was responsible for 
medicines regulation until June 1999 when a new 
regulation called the “Drug Administration and 
Control Proclamation No. 176/1999” was 
promulgated on 29 June 1999. Following this 
proclamation, the regulatory component of the 
Pharmacy Department was transformed to an 
independent Drug Administration and Control 
Authority (DACA) of Ethiopia in September 2001 
(12). DACA was re-structured as Food, Medicine 
and Health Care Administration and Control 
Authority (EFMHACA) of Ethiopia by 
“Proclamation No. 661/2009” in 2010 bearing 
additional responsibilities like regulation of food, 
health care personnel and settings (13).  
The rapid growth and development of 
pharmaceutical sector after the downfall of the 
Dergue regime in Ethiopia has led to the majority 
of pharmaceuticals and medical supplies being 
provided by both the public and private sectors. 
Currently, there are 32 plants (small and large 
scale) involved in the manufacturing of 
pharmaceuticals and related products of which 
only 12 are manufacturers of generic finished 
pharmaceutical dosage forms. The remaining are 
involved in the small scale manufacturing of 
medical devices, supplies, laboratory reagents, 
cosmetics, and disinfectants (14). According to 
EFMHACA website (www.efmhaca.gov.et), there 
are 133 importers, 272 wholesalers, 377 
pharmacies, 1699 drug shops and 1392 rural drug 
venders currently existing in Ethiopia.  
Some primary data sources reveal that poor 
quality pharmaceutical products are in the market 
because of in-efficiencies in pharmaceutical 
regulatory functions in Ethiopia (15). In the past 
few years, more than 60% of foreign 
manufacturers have failed to comply with GMP 
and hence marketing authorization (16). In the 
area of post-registration testing, low income 
countries tended to collect fewer samples and 
report higher rates of products failing testing (17).  
For example, the result of trend analysis on the 
quality control laboratory tests carried out in 
Ethiopia for samples submitted from the year 
2007-2011 shows that most failures of samples 
submitted for post-marketing surveillance (PMS) 
was higher (9.5%-15.5%) than samples submitted 
for the purpose of marketing authorization (4.7% - 
10.7%) (16). Such public health problems should 
thus be investigated through critical evaluation of 
the legal basis and implementation of the 
pharmaceutical regulatory framework in Ethiopia. 
Regular regulatory systems assessment is 
important for the policy makers in designing or 
updating policies and strategies to prevent public 
health from medicines whose safety, efficacy and 
quality are not ensured and authorized to circulate 
in the market. The legal basis of the existing 
pharmaceutical regulatory system in Ethiopia was 
critically reviewed in comparison with relatively 
good regulatory systems of three African countries 
(South Africa, Tanzania and Uganda) and the 
current EU regulatory system. The 
comprehensiveness of the legislation to protect the 
public health was critically evaluated and its 
practical implementation was assessed through 
institution-based cross-sectional survey.  
 
METHODS AND MATERIALS 
 
The study was conducted to critically assess the 
legal framework of the pharmaceutical regulatory 
system based on Proclamation No.661/2009 and 
its implementation status on the institutions 
regulated under the national medicine regulatory 
authority of Ethiopia. An archival review, in-depth 
interviews (with key informants selected from 
institutions involved in the pharmaceutical sector) 
and institution-based cross-sectional survey using 
semi-structured questionnaires developed based on 
WHO guideline were used to gather data (18,19). 
A critical review on the drug regulation was 
undertaken followed by semi-structured interviews 
with key informants from academia, industry and 
EFMHACA to supplement information gathered 
from the legal sources.  





For the review process, archival review guide was 
used as a data collection tool. The tool was 
developed based on WHO guideline (20) and 
contains detail description on the general content 
of the medicine legislation and a checklist for the 
functions of the medicine regulatory authority as 
evaluation points. The basic purpose for 
record/archival review was to assess the 
comprehensiveness of the legal framework to 
protect public health in comparison to medicine 
regulatory authorities (MRAs) of three selected 
African countries (South Africa, Tanzania and 
Uganda) and EU’s European Medicines Agency 
(EMA).  According to a study conducted by WHO 
in 2006, South Africa had a “fully functional” 
MRA, where as Uganda had a “functional” MRA. 
The study further reported that the MRA of 
Tanzania and Ethiopia had “potential for effective 
regulation” (21). Therefore, the selection of the 
three African countries was based on this literature 
while EU was selected for its strict medicine 
regulatory system.  
The review process further assessed the 
availability of basic resources to implement the 
medicines law in relation to marketing 
authorization/regulatory approvals and regulatory 
inspections/enforcement in Ethiopia. Overall, 
records on legal framework, resource for 
implementation and implementation reports in 
protecting public health were assessed. Financial 
and human resource documents, registry for 
regulatory approval/marketing authorization of 
medicines, breaches of the law related to 
unauthorized medicines and their sources, and the 
associated regulatory measures taken on violations 
in comparison to penalties provided in the 
legislation and guidelines were the other focus 
areas in the record review. Moreover, references 
on quality of products from the national market 
were included. 
The purpose of in-depth interview was to get 
details and new insights from the right sources. A 
total of 12 key informants selected from different 
institutions in Ethiopia (EFMHACA, custom 
authority, Ethiopian pharmaceutical association, 
Ethiopian druggist association, Ethiopian 
pharmaceuticals manufacturers association and 
academia) were interviewed. In-depth interviews 
were conducted with individuals selected based on 
their involvement in the regulatory system, and/or 
role as a representative of an industry or 
stakeholder group. Interviewees were based within 
different institutions and from various disciplines: 
pharmacy, law, chemistry, food technology and 
management. Several of the individuals 
interviewed were expert participants with work 
experience of more than 20 years while the 
minimum work experience was 10 years. Points of 
interview included: (1) the problems related to 
safety, efficacy and quality pharmaceuticals in the 
market; (2) government’s political commitment at 
different levels; (3) adequacy and 
comprehensiveness of the current legal provision 
in addressing all the pharmaceutical regulatory 
activities; (4) the capacity and organization of the 
regulatory system at various levels in terms of 
resources and regulatory infrastructures; (5) 
cooperation and collaboration between these 
medicine regulatory bodies at different level and 
their collaboration with other law enforcing 
agencies such as customs, police and judiciary 
bodies; and (6) the public support for medicine 
regulation particularly in reporting illegal 
medicines circulation. 
 Institutional-based cross-sectional survey 
was conducted to assess the implementation of 
those regulatory functions described in the 
legislation. Semi-structured questionnaire 
developed based on WHO guideline containing 
personal information, details of general 
information on medicines regulation, and 
unauthorized sources and/or products if any was 
used to collect data. The institutions-based cross-
sectional study was conducted during March to 
April 2013 to assess the existing regulatory system 
and its implementation status in Ethiopia. The 
source population consisted of all pharmacy 
professionals working in EFMHACA and 
institutions regulated by EFMHACA. Selected 
pharmacy professionals from EFMHACA with 
work experience of two years and above as well as 
technical managers and marketing personnel of the 
regulated institutions were included in the study.  
There were 346 institutions regulated by 
EFMHACA, from which a sampling frame of 30% 
(n = 105) was randomly selected for the study.  
From each of the 105 institutions, two study 
participants were purposively selected. Out of a 
total of 84 pharmacy professionals in EFMHACA, 
52 participants were included. One hundred and 
ninety-seven technical and marketing managers 




participated in the study, making the total number 
249. 
Quantitative data were edited, coded, and 
analyzed using SPSS Statistics version 16.0 
software. Descriptive analyses were conducted 
and outputs were presented using frequency tables 
and charts. The data obtained from key 
informants’ interview were summarized, analyzed 
and presented in a descriptive way per thematic 
area. Similarly, summaries were made from the 
archival review findings on the critical features of 
medicine regulation. A multivariable logistic 
regression was used to investigate the relationship 
between the different reported factors for the 




The legal basis of pharmaceutical regulation in 
Ethiopia: archival review  
Legal framework: An overview of medicines 
regulatory framework in Ethiopia, Tanzania, 
Uganda, South Africa, and EU is presented in 
Table 1, while the legal framework of the 
respective medicine regulatory authorities is 
presented in Table 2. For all the countries, there 
exists a well-defined law for medicine regulation 
with clearly articulated objectives of protecting 
public health from unsafe, inefficacious and poor 
quality medicines. The medicine legislation of 
Ethiopia is based on proclamation 661/2009 with 
the objective of safeguarding and protecting the 
public health through ensuring that all medicines 
(produced locally or imported) that circulate in the 
market and used in the country are safe, effective 
and consistently meet the acceptable quality 
standards. 
In Ethiopia, the Parliament approves 
proclamations, while regulations are approved by 
Council of Ministers similar to that of Tanzania, 
Uganda and South Africa. In EU, legislations and 
directives are all approved jointly by the European 
Parliament and the Council of EU.  
 
Governing body: A good medicines law creates 
administrative governing bodies to put rules in to 
practice (22). In all the studied countries 
(Ethiopia, South Africa, Tanzania, Uganda and 
EU), medicine legislations ensure legal provisions 
for the establishment of a governing body called 
MRA responsible for enforcing the legislation. 
EFMHACA is empowered by the Council of 
Ministers Legislation 189/2010 as the governing 
body for medicine regulation in Ethiopia with its 
organizational structure presented in Figure 1. 
Food and Drugs Administration (TFDA), National 
Drug Authority (NDA) and Medicine Control 
Council (MCC) in Tanzanian are the executive 
organs to enforce medicines law in Tanzania, 
Uganda and South Africa, respectively. The 
European Medicines Agency (EMA) is 
responsible for enforcing medicines law in EU.   
The overall responsibility and accountability 
for all aspects of medicine regulation is given to a 
single agency in Tanzania, Uganda, South Africa 
and EU, while it is distributed horizontally 
between EFMHACA and the Ministry of 
Agriculture and Rural Development, and vertically 
between EFMHACA and regional state regulatory 
bodies (RRBs) in the case of Ethiopia. The 
Ministry of Agriculture and Rural Development is 
responsible to regulate veterinary medicinal 
products, whereas RRBs are responsible to 
regulate establishments in the distribution chain 
except importers and wholesalers.  
 
Regulatory provisions to MRAs 
 
The content and domains of regulations of 
Ethiopia, Tanzania, Uganda, South Africa and EU 
is presented in Table 3. In terms of its content and 
domain of regulation, Poclamation 661/2009 of 
Ethiopia covers most of the critical features for 
medicine regulation with provisions for the major 
regulatory processes. Pharmaceuticals are subject 
to numerous controls at all levels, and EFMHACA 
is granted to regulate their manufacture, 
distribution, marketing, prescription, labeling and 
dispensing. However, there were some differences 
between legal provisions in Ethiopia and the other 
countries whose legislations were reviewed for 
comparison. The variations lie on the domains of 
regulation like scope of regulated products (e.g. 
veterinary medicines are excluded from 
EFMHACA), price control and overall 
responsibility distribution for medicines 
regulation. 





Table 1: An overview of the medicine regulatory framework in the selected countries 
 
# Features Ethiopia Tanzania Uganda South Africa EU 
1 Current medicine law of the 
country 
Food, Medicine 







cosmetics Act No. I 
of 2003 
The national drug policy and 
authority act establish a 
national drug policy and a 
national drug authority. 





Act 101 of 1965 as 
amended act 59 of 




(Regulation (EC) No. 
726/2004) 






and poor quality 
medicine 
To ensure that only 
safe, quality and 
efficacious 
products are 
approved for use in 
the country. 
To ensure the availability at all 
times of essential, efficacious 
and cost-effective drugs to the 
entire population of Uganda 




intended for human 
and animal use 
Protection of public 
health on the basis of 
scientific criteria of 
quality, safety and 







Parliament  Parliament  Parliament Parliament European  
parliament/the council 
of EU Regulations/ 




advise of TFDA 
Ministry upon advise of NDA Department of 
Health 
Guidelines  EFMHACA TFDA NDA MCC EMA 
Official 
 Journal 
Negarit Gazette Gazette Gazette Gazette Official Journal for EU  
L 136 




TFDA NDA MCC EMA, EDQM, 
national competent 
authorities 
EFMHACA: Food, medicine and healthcare administration and control authority of Ethiopia; TFDA: Tanzania food and drug administration; NDA: National drug authority of 












Table 2:  The legal framework of the medicine regulatory authorities (MRAs) 
 
 Ethiopia Tanzania Uganda South Africa  EU 
Legal status of the 
regulatory authority 
A A A B  A 
Main regulatory 
authority 
EFMHACA TFDA NDA MCC  EMA 
Supervisory body MOH and RHB MOH MOH MOH  MOH 
Links with other local 
regulatory agency 
MOARD & RRB NA NA NA  Member 
states 




Single agency  Single 
agency 
Power to hire or fire 
personnel 
Yes* Yes Yes Yes  Yes 
Financial independence Yes Yes Yes Yes  Yes 
A = semi-autonomous statutory authority under Ministry of Health (MOH), B = council under MOH, NA = not 




Figure 1: Organizational structure of Food, Medicine and Health care Administration and Control 
Authority of Ethiopia 
 





Table 3: Content of medicine laws and some regulatory activities of Ethiopia, the three African countries and EU 
 
# Content of the law Ethiopia Tanzania Uganda South Africa EU 
1 Product classification Human medicine ● ● ● ● ● 
Veterinary medicine ○ ● ● ● ● 
Medical devices ● ● ● ● ● 
Blood & blood products ● ● ● ● ● 
Tissue transplant ● ● ● ● ● 
Cosmetics ● ● ● ● ● 
Narcotics & psychotropic ● ● ● ● ● 
Herbal products ● ● ● ● ● 
Functional foods ● ● ● ● ● 
Food and additives ● ● ● ● ● 
ATMP ○ ○ ○ ○ ● 
Border-line products ○ ○ ○ ○ ● 
2 Regulatory functions       
2.1. Product assessment and registration Human medicine ● ● ● ● ● 
Veterinary medicine □ ● ● ● ● 
Herbal products  ● ● ● ● ● 
Biological products ● ● ● ● ● 
Cosmetics ● ● ● ● ● 
Foods and additives ● ● ● ● ● 
2.2. Premise licensing  Manufacture ● ● ● ● ● 
Importers /wholesalers ● ● ● ● ● 
Retail outlets ○ ● ● ● ● 
 2.3. Inspections GMP inspection ● ● ● ● ● 
Supply chain inspection ○a ● ● ● ● 
2.4. Quality control ● ● ● ● ● 
2.5. Pharmacovigilance ● ● ● ● ● 
2.6. Control of product promotion ● ● ● ● ● 
2.7. Clinical trial control ● ● ● ● ● 
2.8. Import/export control ● ● ● ● ● 
2.9. Price control ○ ● ● ● ● 
2.10. Sources of products regulated Private manufacture ● ● ● ● ● 
Government manufacture ● ● ● ● ● 
Private import ● ● ● ● ● 
Government import ● ● ● ● ● 
2.11. Control of raw materials Active pharmaceutical ingredient  ● ● ● ● ● 
Excipients ● ● ● ● ● 
2.12. Registration harmonization  ○ EAC and SADC EAC EAC and SADC ICH 
ATMP: Advanced therapy medicinal products; Border-line products: between medicinal products and food supplements, biocides, cosmetic products or medical devices. 
●Present; ○Absent; EAC: East African community; SADC: South African development communities; ICH: International conference on harmonization; □not under FMHACA; aExcept 
importer/wholesalers, lower supply chains are regulated by regional state regulatory bodies in Ethiopia 




Product classification: Pharmaceutical 
legislations provide product classifications based 
on definitions for medicines or medicinal 
products. Product classification is important for 
executing pharmaceutical laws governing 
production, marketing and utilizations of 
medicines.  
According to Article 1 of Directive 
2001/83/EC of EU, a medicinal product is defined 
as: (a) any substance or combination of substances 
presented as having properties for treating or 
preventing disease in human beings/animals; 
and/or (b) any substance or combination of 
substances which may be used in, or administered 
to, human beings, either with a view to restoring, 
correcting or modifying physiological functions 
by exerting a pharmacological, immunological or 
metabolic action, or to making a medical 
diagnosis. Moreover, Article 2(2) of the Directive 
provides classification of a product into a 
medicinal product, where doubt remains as to its 
classification as a medicine or another type of 
product; but the European Court of Justice 
judgment is helpful. Product classification in EU 
considers presentation and/or purpose/function 
aspects of the products.  
Article 2(6) of Proclamation No. 661/2009 of 
Ethiopia defines medicine as any substance or 
mixture of substances used in the diagnosis, 
treatment, mitigation or prevention of a disease in 
human. It includes narcotic drugs, psychotropic 
substances and precursor chemicals, traditional 
medicines, complementary or alternative 
medicine; poisons, blood and blood products, 
vaccine, radioactive pharmaceuticals, cosmetics 
and sanitary items and medical instruments.  
Product classification in Ethiopia (and the 
three African countries) addresses only the 
functional issue of products and neglects the 
presentation aspects, which are well described in 
EU. It poses greater challenges to classifying 
products that are on the borderline between 
medicinal products and food supplements, 
biocides, cosmetic products and medical devices. 
Moreover, advanced therapy medicinal products 
(ATMP) like gene therapy, somatic cell therapy 
and tissue engineering are not classified in 
Ethiopia, Tanzania, Uganda and South Africa. 
Therefore, EU’s product classification is much 
broader and provides a wider scope of products to 
be regulated under the law. 
 
Product assessment and registration 
 
Medicines registration, also called marketing 
authorization, is often a major element in national 
pharmaceutical law. It is carried out by MRAs to 
ensure that a medicinal product has been 
adequately tested and evaluated for safety, 
efficacy and quality; and the product information 
provided by the manufacturer is accurate.  
The comparative presentation of market 
authorization by EFMHACA, TFDA, NDA, MCC 
and EMA is given in Table 4. All the MRAs have 
a legal basis for marketing authorization of the 
pharmaceutical products with guidance for 
applicants and standard operating procedures for 
assessors. Except EFMHACA, all the MRAs make 
use of external experts in the form of various 
committees and are involved in regional or 
international harmonization of registration 
process. EFMHACA has a single advisory 
committee, and is not currently participating in 
regional harmonization for registration, even 
though Ethiopia is very recently working towards 
harmonization of quality assurance for 
pharmaceutical and medical products with 
Intergovernmental Authority on Development 




















Table 4: Marketing Authorization process in five regulatory authorities 
 
Particulars  Countries 
  
Ethiopia Tanzania Uganda South 
Africa 
EU 
Legal basis  for authorization ● ● ● ● ● 
Guidance for applicants  ● ● ● ● ● 
SOP for assessment ● ● ● ● ● 
Advisory committee(s) □ ● ● ● ● 
Assessors      
External Assessors ○ ● ● ● ● 
Full time assessors ● ● ● ● ● 
Legal provision to publish list of approved 
products  
● ● ● 
 
● ● 
Recognition of  other MRA decision ●
s
 ● ● ●
s
 ● 
Harmonization of registration ○ EAC 
SADC 
EAC SADC ICH 
 
Fast track registration ● ● ● ● ● 
Collect fee for application ● ● ● ● ● 
Target time frame to assess (in Months)      
New medicines  6 12 24 7 
Generic medicines  6 4.5 12 1 
Fast track applications  6 1.5 6 ● 
Registration validity period (years) 4 5 1 5 5 
S: Stringent MRA and recognized by WHO prequalification program; ●: Yes, ○: No; □: Yes but not functional during the 
assessment; SADC: Southern African Development Communities; EAC: East African Community: ICH: International Conference 
on Harmonization 
 
Article 20 of Regulation 299/2013 of Ethiopia 
grants special permit for importation of 
unregistered medicinal products for clinical trials, 
scientific investigations, personalized use of a 
patient, laboratory quality testing for the purpose 
of registration, disaster and emergency aids, 
diplomatic missions and treatment of diseases with 
no adequate attention. although very limited, EU 
also provides exceptions for medicinal products 
for clinical trials, emergency situation and 
compassionate use. 
Similar to other MRAs, the market 
authorization process in Ethiopia includes 
manufacturing premise inspection for GMP 
compliance, assessment of product dossiers and 
laboratory testing, where applicable. The 
requirements for Ethiopian market authorization 
are: (1) the medicinal product has to be included 
in to national medicine list; (2) the manufacturing 
site has to be approved and certified for 
compliance with GMP either by EFMHACA or 
other recognized stringent regulatory authorities 
and (3) such GMP certified or waived 
manufacturers have to submit application for 
dossier evaluation and product quality assessment 
accompanied with application fee.  
 
Licensing and inspection: Law should create 
mechanisms to ensure that relevant parties are 
licensed and inspected so that the community can 
have confidence in them (22). Proclamation 
661/2009 states that the involvement of any 
person or institution in the pharmaceutical sector 
without being authorized or licensed is legally 
prohibited. A breach of law to trade medicine 
without certificate of competence shall be 
punishable with imprisonment of 5-7 years and 
fine of 2,700-5,400 USD (15).  
Medicines retail outlets and supply chain 
inspections are mandated to RRBs, while 
EFMHACA is responsible for manufacturers, 
importers and wholesales inspection and licensing 
unlike TFDA, NDA, MCC and EMA. Moreover, 




the EFMHACA proclamation does not include 
requirements for obtaining licenses, terms and 
conditions for suspending or revoking activity and 
product licenses. It does not define the norms, 
standards and specifications to be applied in 
assessing the quality, safety and efficacy of 
medicinal products. These points and other similar 
details were left to be stated in the directives and 
guidelines to be prepared by EFMHACA based on 
the proclamation. 
A review of 2010-2012 performance and 
activity reports indicated that EFMHACA is 
striving to exercise the legal mandate through 
preparations and approvals of different directives, 
standards, guidelines, standard operating 
procedures and check lists. Accordingly, the 
authority has prepared 39 standards, 14 directives 
and various guidelines in the last three years since 
proclamation 661/2009 has been enacted.  
 
Control of raw materials: Proper quality 
management of pharmaceutical raw materials and 
excipients during collection,  import, export, 
transport, distribution, storage, processing and 
documentation is a base to obtain safe, efficacious 
and good quality pharmaceutical products. 
Therefore, the source, origin and suitability of the 
starting material should be clearly defined and 
controlled.  
In all the assessed MRAs, the finished 
pharmaceutical product (FPP) manufacturers are 
responsible for the control of raw materials (active 
pharmaceutical ingredients (APIs) and excipients). 
For EU, all imported active substances must have 
been manufactured in compliance with standards 
of good manufacturing practices (GMP) at least 
equivalent to the GMP of the EU (23), whereas for 
Ethiopia, compliance with Pharmacopoeia 
specifications and GMP procedures is adequate. 
 
Implementation of medicines regulation in 
Ethiopia: The implementation status of 
medicines regulatory system in Ethiopia was 
addressed. The results of both in-depth 
interview of key informants and institutions-
based cross-sectional survey were used to 
evaluate its implementation.  
 
Key informants perspective: All the key 
informants agreed that Proclamation 661/2009 is 
comprehensive in addressing all the 
pharmaceutical regulatory activities to protect 
public health. However, they stressed that the 
important regulatory tools that enable 
implementation of the proclamation have to be 
put in action since the sole existence of the law 
does not ensure its implementation.  
 
Government’s political commitment: All the 
key informants believe that there is strong political 
commitment from the government to support the 
pharmaceutical sector in general and the 
regulatory system in particular. The Government 
has already denoted the regulatory system as one 
of the pillars in the health sector. It produced 
provisions of proclamation for regulation of the 
pharmaceutical sector, empowered the regulatory 
authority to hire staff and acquire resources, 
established procurement system to supply 
government health institutions with 
pharmaceuticals and planned to enhance local 
production in its growth and transformation plan 
(GTP). The GTP capacitates local manufacturers 
and attracts investors to the pharmaceutical sector. 
However, the informants emphasized that more 
should be done to establish a strong medicine 
regulatory mechanism. According to them, the 
physical existence of the law, unless supported 
with a proper organization, qualified human 
resource and adequate finances, is not a guarantee 
for effective medicines regulation.  
 
Product smuggling: According to the key 
informants, pharmaceutical products smuggling is 
recently emerging in Ethiopia and much 
worsening in remote areas of the country due to 
weak customs control. Some even claimed that 
they had observed similar problems even in the 
central part of the country including Addis Ababa.  
The key informants mentioned that legally 
imported products were also diverted to the 
private sector. Some added that the problem was 
not only smuggling, but also the condition in 
which such products were transported and stored. 
The smuggled products are usually transported 
using animals through deserts without any care for 
the storage conditions, which could cause further 
damage or degradation to these products.  
The majority of the key informants believed 
that both professionals and non-professionals in 
the legal and illegal institutions were stakeholders 
and responsible for the problems. Although some 
importers and distributors may be involved, the 
primary destinations of such illegal products were 





retail outlets and unregulated markets from which 
they were dispensed to the end users. Some of the 
key informants claimed that clinics were providing 
diagnostic and pharmaceutical services together 
for which they were not licensed.  
As per the key informants, the main factors 
contributing to the existence of illegal products in 
the market were weak regulatory enforcement 
(64.5%), poor inter-agency cooperation between 
law enforcing bodies (62.2%) and weak boarder 
control (50%). Decentralization of the regulatory 
activities to lower-level administrations with weak 
control capabilities created regulatory gaps and 
contributed for smuggling or diversion of the 
pharmaceutical products in Ethiopia. 
 
Harmonization with-in law enforcing agencies 
at various administrative levels: Efforts of 
cooperation have been undertaken between 
medicine regulatory bodies at federal, regional 
states and other law enforcing agencies according 
to the EFMHACA informants. However, there is 
no established system with clearly defined roles 
and responsibilities of parties involved including 
inter-agency standard operating procedures. The 
informants added that in particular there is weak 
cooperation between the authority and the 
prosecutors at court, and thus most illegal cases 
taken to court were not successful. 
 
Cross-sectional survey: Data were collected from 
a total of 249 respondents using self-administered 
questionnaire with the response rate of 94.3%. The 
majority of the institutions, 175(71.1%), were 
from the central part of the country, i.e. Addis 
Ababa and its surrounding. This was because the 
majority of the institutions were concentrated 
around the capital.  
 
Awareness about medicine regulation in 
Ethiopia: Of the total 249 respondents, 
197(79.1%) were not staff of EFMHACA, of 
which only 83(42.1%) reported awareness about 
the current medicine legislation of Ethiopia. The 
majority, 67(80.7%), of those who had awareness 
reported that the medicine legislation is 
comprehensive enough to cover important 
pharmaceutical regulatory activities to protect 
public health.  
 
Resources for medicine regulation: The study 
participants were EFMHACA staff members. 
They revealed that there is significant shortage of 
qualified and skilled human resource for medicine 
regulation in Ethiopia. Low salary, lack of 
attractive career structure and incentives were 
reported to be the leading contributing factors to 
problems in hiring and retainining qualified and 
skilled personnel within the regulatory system. 
Regarding the financial resources, the study 
participants confirmed that there was no adequate 
financing to perform the routine regulatory 
activities. This was due to insufficient government 
funding and weak revenue generating system from 
services, even though EFMHACA is mandated to 
use the revenue it generates from service delivery.  
 
Unauthorized medicines sources: Out of the 
total respondents, 102(41.0%) reported that there 
were institutions and/or individuals involved in 
pharmaceutical business without being authorized 
or licensed to provide such services. According to 
the study participants, these unauthorized/illegal 
institutions are involved in importat and 
distribution to the medicine retail outlets 
(pharmacies, drug shops, rural drug venders, 
clinics), and even dispensing directly to the users. 
The study revealed that there were unauthorized 
sources for pharmaceutical products in all the 
major commercial cities of the country; with the 
majority existing in the eastern part (71.4%, 10 of 
14) followed by the northern region (53.6%, 15 of 
28) of the country.  
 
Illegal pharmaceutical products: Seventy0eight 
(31.3%) respondents reported that illegal 
pharmaceutical products were circulating in the 
pharmaceutical market of the country in the last 
12 months preceding the study. It was reported 
that illegal pharmaceutical products enter into 
the distribution channel either through legal or 
illegal ports. However, the majority of the 
respondents believed that these products enter 
through illegal entry routes as presented in Figure 
2. 
 






Figure 2:  Reported entry route and destination of illegal products, Ethiopia, March 2013 
 
The majority of the study participants (158, 
63.5%) reported that the main contributing factor 
for the presence of illegal sources was weak law 
enforcement. All the reported factors are presented 
in Figure 3. Anti-infective medicines (50%) were 
the most frequently reported illegal 
pharmaceutical products (from which anti-malarial 
medicines cover more than a third) followed by 
hormonal drugs (insulin and oral anti diabetics, 
and sex hormone preparations) and contraceptives 
(21%).   
In a binary logistic regression analysis, 
variables such as, inadequate law 
enforcement/regulatory measures on illegal 
institutions, lack of informal market control, poor 
control at entry ports, poor cooperation between 
FMHACA and regions, availability of illegal 
medicines, extra profit from illegal products and 
reporting illegal product were found to have 
significantly association (p < 0.05 at 95% CI) with 
the existence of illegal institutions in the 
pharmaceutical sector of the country (Table 5). 
From the multivariate logistic regression analysis 
performed on these variables, it was found that 
inadequate regulatory measures (enforcement), 
lack of informal market control, availability of 
illegal pharmaceutical products and location (site) 
of the country from the entry ports remained 
significantly associated with the existence of 
illegal institutions.  
 
 
Figure 3: Factors contributing to the availability of illegal pharmaceutical sources, Ethiopia, 
March 2013 









Existence of illegal 
institutions 
Crude OR (95%CI) 
p-value 
Adjusted OR (95%CI) 
 p-value 
Yes No 
Inadequate regulatory measures 
Yes 84(53.2%) 74(46.8%) 4.35 (2.38, 7.97) 0.000 3.50 (1.84, 6.65 ) 0.000 
No 18(20.5%) 70(79.5%) 1.00  
Port control     
Yes 42(34.1%) 81(65.9%) 1.00 1.00 
No 60(48.8%) 63(51.2%) 1.84 (1.09, 3.03) 0.023 1.13 (0.63, 2.03) 0.689 
Lack of informal market control 
Yes 74(49.7%) 75(50.3%) 2.40 (1.39, 4.1) 0.002 1.97 (1.08, 3.60) 0.027* 
No 28(28.9%) 69(71.1%) 1.00 1.00 
Lack cooperation b/n FMHACA & regions 
             Yes  50(33.6%) 99(66.4%) 1.00 1.00 
             No 52(53.6%) 45(46.4%) 2.29 (1.35, 3.87) 0.002 1.56 (1.00, 3.40) 0.153 
Illegal product exist 
Yes 46(59%) 32(41%) 2.88 (1.65, 5.00) 0.000 2.79 (1.52, 5.11) 0.001 
              No 56(33.3%) 112(66.7%) 1.00 1.00 
Reporting illegal product 
Yes 20(60.4%) 13(39.4%) 1.00 1.38 (0.53, 3.74) 0.532 
No 82(38.5%) 131(61.5%) 2.46 (1.16, 5.21) 0.019  
Extra profit from illegal product 
Yes 50(49%) 52(51%) 1.68 (1.00, 2.82) 0.048 1.04 (0.57, 1.90) 0.892 
No 52(36.1%) 92(63.9%) 1.00 1.00 
 
Inadequate regulatory measures/enforcement on 
violations was found to be strong contributing 
factor for the existence of unauthorized sources. 
Illegal institutions or individuals are more than 
three times significantly likely to exist in the 
pharmaceutical market when regulatory 
measures/enforcements are inadequate than when 
such measures are adequate (AOR = 3.5, 95% CI 
= (1.84, 6.65), at p < 0.001). Similarly, illegal 
institution are two times more likely to exist in the 
pharmaceutical market when informal market is 
unregulated than when it is regulated (AOR = 
1.97, 95% CI = (1.08, 3.595 at p < 0.05). The 
illegal sources are three times significantly more 
likely to exist in the presence illegal 
pharmaceutical products circulating in the market 
(AOR = 2.785, 95% CI for OR (1.52, 5.11), at p ≤ 
0.001). 
The majority of the respondents claimed that 
they did not usually report the presence of illegal 
pharmaceutical institutions (53.9%, 55/102) and 
products (59.0%, 46/78). Details on awareness and 
reporting practice of the respondents is presented 
in Table 6. The main reasons for not reporting the 
problems were lack of formal reporting system, 
fear of security problems from smugglers, absence 
of legal measures for previous reports and lack of 
















Table 6: Awareness and reporting practice of respondents on problems related to pharmaceutical products in 
the market, Ethiopia, March 2013 
 
Problems related to pharmaceutical product Aware of problem Reported problem 
Frequency              (%)* 
Illegal institutions Yes 102(41.5%) Yes 47(46.1%) 
No 144(58.5%) No 55(53.9%) 
Total 246 Total 102 
Illegal products Yes 78(31.7%) Yes 32(41%) 
No 168(68.3%) No 46(59%) 
Total 246 Total 78 
Safety problems Yes 98(39.8%) Yes 32(32.65%) 
No 148(60.2%) No 66(67.35%) 
Total 246 Total 98 
Drug abusers Yes 38(17%) Yes 13(34.2%) 
No 186(83%) No 25(65.8%) 
Total 224 Total 38 
Misleading/in-accurate 
 medicine promotion materials 
Yes 43(17.5%) Yes 18(41.9%) 
No 203(82.5%) No 25(58.1%) 
Total 246 Total 43 




An effective national pharmaceutical law is a 
primary means of ensuring that pharmaceutical 
policy goals are achieved with the unique 
character of pharmaceutical products, personnel 
and facilities is preserved. Therefore, when 
assessing the pharmaceutical regulatory system in 
Ethiopia from the legislation point of view, in 
terms of its purpose and content, evaluation of the 
framework based on WHO-standards and 
comparative review with other countries (Table 3) 
showned that the medicine legislation in Ethiopia 
provides basic legal framework and covers all 
products for which medicinal claims are made, as 
well as related pharmaceutical activities, in both 
the public and private sectors. In line with this, the 
cross-sectional study revealed that the legislation 
is comprehensive enough to cover all 
pharmaceutical regulatory activities important to 
protect public health.  
Considering the significant public health 
implications of veterinary medicines in human 
health, the legislation in Ethiopia does not have 
provisions for the control of veterinary medicines 
in contrast to all other countries with which the 
comparative review was conducted. However, 
Ethiopia has a separate authority called veterinary 
drugs and animal feed administration and control 
authority established by Proclamation No. 
728/2011 to regulate the proper production, 
distribution and use of veterinary drugs to ensure 
safety, efficacy and quality of the products and to 
enhance the productivity and health of the 
livestock population. In fact, there should be at 
least exchange of information between this 
authority and EFMHACA with regard to full 
regulation of products, premises and practicing 
personnel. 
The Ethiopian legislation mandated EFMHACA 
to prepare and approve or submit to appropriate 
organ for approval of regulatory standards and 
specifications to be applied in assessing the 
quality, safety and efficacy of medicinal products, 
and upon approval, to ensure the implementation. 
Accordingly, a number of guidelines including 
guidelines for human medicine evaluation, 
registration, and premises licensing and inspection 
have been prepared by EFMHACA got approval. 
However, the problem with such mandate is that 
guidelines approved by the regulatory authority 
are only administrative tools rather than statutory 
instrument in the court unless approved by the 
Council of Ministers, which in turn has an 
influence on enforcement of the law. Moreover, 
there were no reports found on joint operations 
between EFMHACA and other law enforcing 





agencies such as police and custom authority and 
this could be taken as additional evidence for lack 
of inter-agency cooperation in Ethiopia, which are 
very critical for effective medicine regulation (5, 
8). Such operational cooperation was reported in 
other African countries and the experience in 
Uganda revealed a success story. A number of 
unregistered drug outlets were uncovered, and 
many counterfeit products were identified during 
joint operations between law enforcing agencies 
(MRA, customs, and police) in 2007-2011 in 
Uganda (24). The other major finding was that the 
responsibilities for pharmaceutical regulation in 
Ethiopia are distributed horizontally between two 
ministries and vertically between federal and 
regional state governments. Such fragmented 
systems among agencies could lead to overlap of 
responsibilities and regulatory ineffectiveness 
(24,25) resulting in wastage of resources in the 
already poor-economy (26).  
Literatures recommend harmonized optimal 
drug registration approach for resource-limited 
settings, which should reliably evaluate safety, 
efficacy and quality of drugs for use (27-29). 
However, Proclamation 661/2009 of Ethiopia does 
not have any article on regulatory harmonization 
with respect to market authorization unlike that of 
Tanzania, Uganda, South Africa and EU. 
However, currently Ethiopia is working towards 
possible harmonization among the IGAD member 
states on policy framework and regulatory system 
for pharmaceuticals and medical products quality 
assurance.   
Although medicine legislation in Ethiopia 
prohibits the involvement in medicine trade 
without being licensed and sales by licensed 
importer and wholesaler to person or institution 
without certificate of competence, there exist 
institutions and/or individuals involved in 
pharmaceutical business without being certified to 
provide such services. Illegal transits and 
distributions are usually secret for regulatory 
inspections by customs or medicine regulatory 
bodies (30), and their existence could not only 
indicate inefficiencies in regulating the sector but 
also the presence of either unauthorized sources of 
medicine to the country or pharmaceuticals 
diversions. Therefore, it is reasonable to assume 
that these unlicensed institutions were the 
destinations for smuggled or diverted 
pharmaceutical products. This is in line with the 
reports of the study participants that such illegal 
institution or individuals are in an informal market 
for medicines, and a similar finding reported the 
existence of non-conventional markets for 
pharmaceutical products in Ethiopia (31), which 
could lead to the high prevalence of poor quality 
medicines.   
The study participants reported that illegal 
medicines included both registered and 
unregistered products of which anti-infective 
medicines take the major share. Among medicines 
imported illegally, it is obvious that some were 
counterfeits and/or substandard. A national quality 
survey study conducted in Ethiopia reported a 
significant proportion of poor quality albendazole, 
mebendazole and tinidazole tablets on the 
Ethiopian market from which 29% was 
substandard (32).  
This study reported diversion of medicines. 
Another study conducted on assessment of anti-
malarial diversion in 11 African cities including 
Addis Ababa showed that 6.5% (58 of 894) 
samples of anti-malarial medicines collected from 
market were found to be diverted across at least 
one national border as determined by visual 
inspection (33). Diversion of medicine primarily 
affects sustainable procurement systems because it 
exacerbates stock outs in public health sector 
exposing patients to extra costs and making 
criminals profitable from diversion.  
Inadequate enforcement of law was found to 
be the leading contributing factor for the presence 
of illegal institutions and/or products. Similarly, 
literatures revealed that inadequate legislation and 
weak or insufficient law enforcement along with 
resource constraints to to effectively implementing 
the law are among the regulatory factors that have 
contributed to the illegal circulation of medicines 
in many countries (34). Experiences in Australia, 
Canada and the United States have shown that 
adequate legislation and its enforcement result in 
fewer poor-quality medicines and greater public 
confidence in the quality of the medicines (30). 
Although the evidence for the feasibility of strict 
regulatory enforcements is very limited in low 
income countries, such interventions to improve 
regulatory compliance was reported to have 
impact on illegal sources in Vietnam and Lao 
Peoples Democratic Republic (35).  
The strength of this study is that it included 
the strict EU regulatory framework and that of 




three African MRAs to evaluate the legal basis of 
Ethiopian pharmaceutical regulation. Moreover, it 
tried to address both the regulator and the 
regulated firms and professionals in the 
pharmaceutical sector. The other strength was the 
geographic coverage of the study, which was 
wider and encompassed the major trade cities and 
parts of the country. 
Most archival data are collected for 
nonscientific reasons and thus often do not suit the 
purpose of the researcher. Moreover, 
pharmaceutical sector regulation is so sensitive 
and obtaining reliable and genuine data could be 
difficult.   
From legislation point of view, it can be 
concluded that medicines regulation as a system in 
place in Ethiopia has potential capacity to develop 
in comparison with EU; and the three African 
countries like South Africa, which was reported by 
WHO in 2006 to have fully functional MRA. 
However, this study revealed that 
unauthorized/illegal medicine sources exist in the 
sector due to some in-efficiencies in the 
implementation of this regulatory system into the 
real practice. For instance, resource constraints as 
a basic factor along with other reported factors 
such as lack of informal market regulation, weak 
enforcement of the law and availability of illegal 
products are regulatory factors. Less reporting 
practice of illegal activities by professionals in the 
sector was also another important factor associated 
with the existence of illegal institutions in the 
pharmaceutical market. 
The majority of medicines reported as 
illegally imported were anti-infective medicines 
including anti-malarial and other antibiotics. 
These reported products included both registered 
and unregistered products. Unregistered products 
do not only escape the necessary government tax, 
but they are also medicines for which quality, 
safety and efficacy are not ensured. Hence, they 
could be counterfeit, substandard and/or degraded 
products because of their transportation and 
storage conditions to hide from customs and 
regulatory authority.  
Proclamation 661/2009 should be amended to 
include critical legislative gaps like 
harmonization. Product classification should be 
revised so that a strong autonomous regulatory 
system should take place. RRBs should have 
mechanisms of cooperating with EFMHACA. 
EFMHACA should improve awareness about the 
current legal provision for medicine regulation. 
Moreover, detail national assessment of 
pharmaceutical malpractices and poor quality 
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